The results suggested that the protein levels of TXNIP, NLRP3, cleaved-caspase-1, IL-18, and IL-1β were significantly enhanced in Ang II-treated AAA, and their levels were inhibited by ADSC-exos, especially in those treated with ExomiR−17−5p mimics. This evidence concerns the gene IL1B and triple-A syndrome.